RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Abstract Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged with a second RAF inhibitor, either as monotherapy or in combination w...

Description complète

Détails bibliographiques

Auteurs principaux:	Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2024-03-01
Collection:	Molecular Cancer
Sujets:	Rechallenge RAF pathway BRAF inhibitors BRAF-altered solid tumors
Accès en ligne:	https://doi.org/10.1186/s12943-024-01982-4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!